News Releases

News Releases

April 2, 2018
ARMO BioSciences Reports FY 2017 Financial Results

First Patient Enrolled in CYPRESS 1 Trial in Non-Small Cell Lung Cancer REDWOOD CITY, Calif. , April 02, 2018 (GLOBE NEWSWIRE) --   ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced its financial results for the fiscal year ended December 31, 2017 .

January 25, 2018
ARMO BioSciences Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif. , Jan. 25, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. ("ARMO"), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of